Edition:
United Kingdom

Biosig Technologies Inc (BSGM.OQ)

BSGM.OQ on NASDAQ Stock Exchange Capital Market

4.75USD
12 Oct 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.75
Open
$4.79
Day's High
$5.17
Day's Low
$4.68
Volume
24,014
Avg. Vol
--
52-wk High
$7.10
52-wk Low
$4.66

Summary

Name Age Since Current Position

Kenneth Londoner

50 2017 Executive Chairman of the Board, Chief Executive Officer

Steven Chaussy

63 2014 Chief Financial Officer

Natasha Russkina

2017 Vice President, Business Development and Corporate Finance

Joseph Rafferty

59 2017 Chief Commercialization Officer

Andrew Filler

2017 Director

Seth Fischer

61 2013 Independent Director

Donald Foley

65 2015 Independent Director

Patrick Gallagher

52 2014 Independent Director

Jeffrey O'Donnell

57 2011 Independent Director

Roy Tanaka

69 2012 Independent Director

David Weild

60 2015 Independent Director

Biographies

Name Description

Kenneth Londoner

Mr. Kenneth L. Londoner is Executive Chairman of the Board, Chief Executive Officer of BioSig Technologies, Inc. He has served as our director since February 2009,as our executive chairman since November 2013 and our chief executive officer since July 2017. He previously served as our chairman and chief executive officer from February 2009 to September 2013. Mr. Londoner has served as the managing partner of Endicott Management Partners, LLC, a firm dedicated to assisting emerging growth companies in their corporate development, since February 2010. From April 2007 to October 2009, he served as executive vice president – corporate business development and senior director of business development and, from November 2009 to December 2010, he served as a consultant to NewCardio, Inc., a medical device designer and developer. Mr. Londoner also served as a director of chatAND Inc. from January 2012 to April 2015. Mr. Londoner is a co-founder and board member of Safe Ports Holdings, Charleston, South Carolina. Mr. Londoner also served as a director of MedClean Technologies, Inc. from November 2008 to September 2010. Mr. Londoner was an investment officer and co-manager of the Seligman Growth Fund, Seligman Capital Fund, and approximately $2 billion of pension assets at J & W Seligman & Co, Inc. in New York from 1991 to 1997. Mr. Londoner graduated from Lafayette College in 1989 with a degree in economics and finance and received his MBA from New York University’s Leonard N. Stern School of Business in 1994.

Steven Chaussy

Mr. Steven Chaussy is Chief Financial Officer of the company. Prior to joining BioSig Technologies, Mr. Chaussy has been the sole proprietor of Anna & Co., Inc., a consulting company that offers financial and accounting services to small publicly traded companies. Mr. Chaussy has an extensive entrepreneurial growth and development background learned from working for Penske Truck Leasing Co., L.P., a subsidiary of Penske Corporation, where his improvements of management and reporting tools have allowed the company to double in size. During his career, Mr. Chaussy also served as Chief Financial Officer to a number of private and public companies. The systems introduced by Mr. Chaussy have been key drivers of profitability and development of international business lines. Mr. Chaussy is a CPA and received his degree in Accounting from Virginia Polytechnic Institute and State University.

Natasha Russkina

Ms. Natasha Russkina is Vice President, Business Development and Corporate Finance of the Company. She is a well-established finance professional. She is the founder and director of Augeous Consulting in Geneva, Switzerland, a firm that provides various levels of business development capabilities to companies in the life science sector. Ms. Russkina has over 13 years of experience in international business development, including over 9 years at IG Group PLC, a British FTSE 250 company and a global leader in online trading. During this time, she was responsible for the Group’s global business development successfully delivering a number of high level projects from opening new international branches to global rebranding, and providing all initial and ongoing business support to 12 international offices in Europe, South Africa and Australia, a business sector, which accounted for 40% of the Group’s revenue. During her career, she had been appointed by the Board of Directors to open a new IT development office in Eastern Europe and was responsible for all parts of operations. During this assignment, the office grew from 14 inherited members of staff to over 135. Ms. Russkina graduated from Samara State University of Economics in Russia in 2002 and holds a MSc. degree in Management and German.

Joseph Rafferty

Mr. Joseph W. Rafferty is Chief Commercialization Officer of the Company. Mr. Rafferty brings to BioSig over 30 years of leadership experience with traditional corporate and emerging growth companies. Having functioned as CEO, GM, VP Global Sales-Marketing, VP Physician Training, VP Sales Training and Director for National Contracts, Mr. Rafferty has created a legacy of building and leading highly successful teams with industry leaders like Pathway Medical, Avinger, ACS/Guidant, CR Bard Vascular/Cardiovascular, Synthes Spine, Sterilox, J&J's Ethicon Mechanical Products (Endo) and, most recently, as CEO of National Medical Sales, LLC.

Andrew Filler

Mr. Andrew Filler has been appointed Director of the Company. Mr. Filler brings to BioSig over 20 years of experience in intellectual property for technology and medical device companies. He currently serves as Partner and General Counsel for Sherpa Technology Group, a leading Silicon Valley IP advisory firm. Prior to this assignment, Mr. Filler served as Vice President of IP for Nanosys, Inc., where he created and managed one of the largest nanotechnology patent portfolios in the world with over 800 patents and applications. Under his leadership Nanosys completed hundreds of multi-million-dollar licensing, equity and collaborative agreements with companies such as Samsung, Intel, LG and Medtronic. Mr. Filler was recently named as one of the top two corporate IP attorneys in Silicon Valley by the San Jose/Silicon Valley Business Journal in 2011 and previously served as chief intellectual property counsel at Caliper Technologies, senior associate attorney at Weil, Gotshal & Manges, and director of intellectual property at Corvascular.

Seth Fischer

Mr. Seth H. Z. Fischer is Independent Director of BioSig Technologies, Inc., since May 2013. He has served as our director since May 2013. Since September 2013, Mr. Fischer has served as the chief executive officer and director of Vivus, Inc., a biopharmaceutical company focusing on the treatment of obesity, sleep apnea, diabetes and sexual health. Prior to that, Mr. Fischer served in positions of increasing responsibility with Johnson & Johnson from 1983 until his retirement in 2012. Most recently Mr. Fischer served as Company Group Chairman Johnson & Johnson and Worldwide Franchise Chairman Cordis Corporation from 2008 to 2012, which included responsibility for Cordis and Biosense Webster, and as Company Group Chairman North America Pharmaceuticals from 2004 to 2007, which included responsibility for Ortho-McNeil Pharmaceuticals, Janssen and Scios. Since 2013, Mr. Fischer has served as an advisor of MedHab, LLC, a medical device limited liability company. From April 2013 to September 2013, Mr. Fischer served on the board of directors of Trius Therapeutics, Inc., a public pharmaceutical company, until it was acquired by Cubist Pharmaceuticals, now a wholly owned subsidiary of Merck & Co., Inc.

Donald Foley

Mr. Donald E. Foley is Independent Director of the Company. He has served as our director since October 2015. Mr. Foley was chairman of the board and chief executive officer of Wilmington Trust Corporation from 2010-2011. Prior to Wilmington Trust Corporation, Mr. Foley was senior vice president, treasurer and director of tax for ITT Corporation, a supplier of advanced technology products and services. Mr. Foley currently serves on the board of directors of AXA Equitable EQAT Mutual Funds and is an advisory board member of M&T Corporation Trust and Investment Committee. In addition, Mr. Foley served on the boards of directors of M&T Corporation from 2011-2012 and of Wilmington Trust Company and Wilmington Trust Corporation from 2007-2011. Mr. Foley holds an M.B.A. from New York University and a B.A. from Union College. He is also a member of the board of trustees of Burke Rehabilitation Hospital and Burke Medical Research Institute, as well as the W. Burke Foundation. Mr. Foley brings extensive financial, economic, capital markets and executive leadership expertise to our board gained through his successful career on Wall Street and the Fortune 500.

Patrick Gallagher

Mr. Patrick J. Gallagher M.B.A., CFA., is Independent Director of BioSig Technologies, Inc., since July 14, 2014. He has served as our director since July 2014. Mr. Gallagher, MBA, CFA, is an accomplished capital markets executive, advisor, and investor with a distinguished record of success in both the public and private markets. He has nearly 20 years of experience on Wall Street and extensive expertise in alternative investments, capital markets, and marketing. Since September 2014, Mr. Gallagher has served as managing director and head of healthcare sales at Laidlaw & Co. (UK) Ltd. Mr. Gallagher serves as a strategic consultant for Kinex Pharmaceuticals, LLC, a biotechnology firm focused on next-generation therapies in oncology and immunology and was the vice president of business development and investor relations from September 2012 to October 2013. In November 2010, he was appointed by broker Concept Capital, a division of Sanders Morris Harris, as a Managing Director and the head of institutional sales. In 2001, Mr. Gallagher co-founded BDR Research Group, LLC, an independent sell-side research firm specializing in healthcare investing, financing and operations, and served as its chief executive officer until November 2010. Prior to 2001, he held various sales positions at investment and research firms Kidder Peabody, PaineWebber and New Vernon Associates. Mr. Gallagher is a CFA charter holder, received his MBA from Pennsylvania State University and holds a B.S. degree in finance from the University of Vermont.

Jeffrey O'Donnell

Mr. Jeffrey F. O'Donnell, Sr., is Independent Director of Company. He has served as our director since February 2015; he had previously served as a director from October 2011 until February 2014. Mr. O’Donnell has extensive experience in the Healthcare industry, merging a solid, traditional corporate background with emerging growth experience. Jeff brings more than 20 years of Board and Chief Executive experience running emerging medical device firms. Businesses under his direct leadership have achieved over $1.5 Billion in value creation from initial public offering of stock or mergers and acquisitions. Currently, Jeff is the President and CEO of Trice Medical. Trice is an emerging growth medical device company developing optical needles used by orthopedic surgeons to diagnose soft tissue damage of joints. In 2008, Jeff started and ran Embrella Cardiovascular, a medical device startup company, which was sold in 2011 to Edwards Lifesciences (NYSE: EW). Prior to Embrella Cardiovascular, Jeff served as President and CEO of PhotoMedex (NASDAQ: PHMD) from 1999 to 2009. Prior to PhotoMedex, Jeff was the President and CEO of Cardiovascular Dynamics. His team took CCVD public on NASDAQ in June of 1996 and purchased Radiance Medical Systems and Endologix (NASDAQ: ELGX). From 1994 to 1995 Jeff held the position of President and CEO of Kensey Nash Corporation (NASDAQ: KNSY). Additionally, he has held several senior sales and marketing management positions at Boston Scientific Corporation, Guidant Corporation and with Johnson & Johnson’s Orthopedic Division. In 2005, Jeff was named LifeSciences CEO of the Year by Price Waterhouse Coopers. In 2011, Jeff was named the Greater Philadelphia Emerging Entrepreneur Of The Year by Ernst & Young. Jeff is a previous director for Cardiac Science (7 yrs.) and Endologix (12 yrs.); he also serves as Chairman of the Board of Strata Skin Sciences (NASDAQ: SSKN).

Roy Tanaka

Mr. Roy T. Tanaka is Independent Director of BioSig Technologies, Inc., since July 2012. He has served as our director since July 2012. From 2004 until his retirement in September 2008, Mr. Tanaka served as the worldwide president of Biosense Webster, Inc., a Johnson & Johnson company, a market and technology leader in the field of electrophysiology. He joined Biosense Webster, Inc. as its U.S. president in 1997. Previously he held a variety of senior management positions at Sorin Biomedical, Inc., including president and chief executive officer, and leadership roles at CooperVision Surgical and Shiley, a division of Pfizer, Inc. He currently serves on the boards of directors of Coherex Medical, Inc. and Advanced Cardiac Therapeutics Inc., a company using electrophysiology to develop technology to measure the temperature in a lesion during cardiac ablation procedures, and VytronUS Inc. In addition, Mr. Tanaka served as a director of Volcano Corporation until May 2014 and Tomo Therapy until its acquisition in June 2011.

David Weild

Mr. David Weild IV is Independent Director of BioSig Technologies, Inc. He has served as a director since May 2015. Mr. Weild is founder, chairman and CEO of Weild & Co., Inc., parent company of the investment banking firm Weild Capital, LLC. Prior to Weild & Co., Mr. Weild was vice chairman of NASDAQ, president of PrudentialSecurities.com and head of corporate finance and equity capital markets at Prudential Securities, Inc. Mr. Weild holds an M.B.A. from the Stern School of Business and a B.A. from Wesleyan University. Mr. Weild is currently on the board of PAVmed. From September 2010 to June 2011, Mr. Weild served on the board of Helium.com, until it was acquired by R.R. Donnelly & Sons Co. Since 2003, Mr. Weild has been chairman of the board of the 9-11 charity Tuesday’s Children.